Results for tag: "Antitrypsin Congenital Deficiency Drug"

Antitrypsin Congenital Deficiency (ACD) is a rare genetic disorder that affects the production of the protein alpha-1 antitrypsin (AAT). This protein is essential for the protection of the lungs and other organs from damage caused by inflammation. As a result, people with ACD are at risk of developing serious respiratory diseases such as emphysema and chronic obstructive pulmonary disease (COPD). The ACD drug market is composed of treatments that aim to replace the missing AAT protein in the body. These treatments include enzyme replacement therapy (ERT) and gene therapy. ERT involves the administration of AAT protein through intravenous infusions, while gene therapy involves the introduction of a healthy gene into the patient’s cells. The ACD drug market is part of the larger Central Nervous System (CNS) Drugs market, which includes treatments for neurological and psychiatric disorders. The CNS Drugs market is highly competitive, with many companies developing innovative treatments for a variety of conditions. Some of the companies in the ACD drug market include Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., and Protalix BioTherapeutics, Inc. These companies are focused on developing treatments for ACD and other rare diseases. Show Less Read more